Sosei Names New CEO
Japanese biopharma Sosei Group Corporation has appointed Peter Bains representative executive officer and CEO, taking over from founder Shinichi Tamura, who has been appointed representative executive officer and executive chair. Bains joins the company from Syngene International Ltd., where he was executive director and CEO. Prior to this, he held leadership positions at several businesses, including Heptares Therapeutics Ltd and GlaxoSmithKline PLC. (Also see "Heptares-Powered Sosei's Incoming CEO Explains What Happens Next" - Scrip, 28 Apr, 2016.)
You may also be interested in...
Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.
New chief business officer named at Ovoca Bio, and a new chairman at Opthea Ltd.
Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.